Tradename: M-M-R II
Proper Name: Measles, Mumps, and Rubella Virus Vaccine Live
Indication: To include safety and immunogenicity data that support the intramuscular route as an additional route of administration for M-M-R II, and associated product labeling changes.
M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older.
Approval Date: 02/27/2023
Manufacturer: Merck Sharp & Dohme Corp.
More: https://www.fda.gov/vaccines-blood-biologics/vaccines/measles-mumps-and-rubella-virus-vaccine-live